GABITRIL (tiagabine hydrochloride) by Teva is mechanism of action the precise mechanism by which tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (gaba), the major inhibitory neurotransmitter in the central nervous system. First approved in 1997.
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
GABITRIL (tiagabine hydrochloride) is an oral small-molecule antiseizure agent approved in 1997 that enhances GABA activity by blocking its reuptake into presynaptic neurons. It is indicated as adjunctive therapy for partial-onset seizures and works by increasing extracellular GABA availability in key brain regions to suppress seizure propagation.
Mature product with shrinking commercial footprint suggests smaller dedicated brand team and likely focus on defensive positioning rather than expansion.
Mechanism of Action The precise mechanism by which tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability, documented in in vitro experiments, to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the…
Worked on GABITRIL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
A 10-Week Efficacy and Safety Study for of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWith zero linked job openings and LOE approaching, career opportunity on GABITRIL is severely constrained; roles are likely in small defensive teams managing market exit or transition. This product offers limited growth potential and is best viewed as a consolidation or cost-optimization assignment rather than a launch or expansion opportunity.